[go: up one dir, main page]

WO2019046919A1 - Composition d'additifs prébiotiques promoteurs de croissance pour rations animales et son utilisation - Google Patents

Composition d'additifs prébiotiques promoteurs de croissance pour rations animales et son utilisation Download PDF

Info

Publication number
WO2019046919A1
WO2019046919A1 PCT/BR2018/050316 BR2018050316W WO2019046919A1 WO 2019046919 A1 WO2019046919 A1 WO 2019046919A1 BR 2018050316 W BR2018050316 W BR 2018050316W WO 2019046919 A1 WO2019046919 A1 WO 2019046919A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
composition
growth
fos
mos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2018/050316
Other languages
English (en)
Portuguese (pt)
Inventor
Victor Abou NEHMI FILHO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yessinergy Holding S/a
Original Assignee
Yessinergy Holding S/a
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yessinergy Holding S/a filed Critical Yessinergy Holding S/a
Publication of WO2019046919A1 publication Critical patent/WO2019046919A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs

Definitions

  • the present invention relates to a composition for growth promoting prebiotic additives which can be used in animal feeds, or as growth promoters, or as nutraceuticals, or as prebiotics, or as additives for the control and prophylaxis of pathogenic bacteria in the intestinal tract of animals , or livestock.
  • Microorganisms in nature are constantly competing for resources (nutrients, space), and for that they use various resources.
  • antibiosis refers to a natural process of selection through which one living being destroys another to ensure its survival.
  • APC growth promoting antibiotic
  • the term derives from the positive effect of the inclusion of antibiotics as food additives, at dosages below that used in the treatment of diseases, on weight gain in animals.
  • Antibiotics are substances produced by fungi, yeasts or bacteria that act against other microorganisms present in the medium, causing the inhibition of their growth.
  • Antibiotics and chemotherapeutics were considered the traditional growth promoters for poultry and swine. A large number of substances have proven effective in improving animal productivity over the past decades, and their use as a feed additive has still been widespread.
  • Antibiotics are the oldest and most successful substances used for the manipulation of the intestinal microbiota. When used in sub-dosages, they eliminate only the most sensitive individuals from some unwanted bacterial species of the intestinal microbiota. With the elimination of these individuals a greater efficiency in the feed conversion is achieved. That is, greater production of animal weight with the same amount of food. For this reason, they are known as growth promoting antibiotics, or APCs.
  • APCs growth promoting antibiotics
  • REPLACEMENT SHEETS (RULE 26) resistance characteristic given by the genes of these microorganisms can be transmitted from one microorganism to another, reaching even the population of the human microbiota through the consumption of contaminated food.
  • EU European Union
  • Non-digestible food ingredients are known as prebiotics for both humans and animals that have the ability to induce the growth or activity of beneficial microorganisms such as the bifid bacteria of the intestinal tract (eg bacteria and fungi), particularly of the colon , improving the health of its host.
  • beneficial microorganisms such as the bifid bacteria of the intestinal tract (eg bacteria and fungi), particularly of the colon , improving the health of its host.
  • Prebiotics act as food for probiotic bacteria.
  • the use of prebiotics as a food ingredient may have a superior beneficial effect to the growth promoting antibiotics, since they do not leave residues in products of animal origin and do not induce the development of drug resistance, since they are essentially natural products.
  • prebiotics are not metabolized or absorbed by the upper digestive tract, serve as a substrate for beneficial intestinal bacteria, stimulating them to grow or becoming metabolically active, alter the intestinal microflora in a health-friendly way of the host and induce the beneficial systemic or intestinal effects of the host.
  • Prebiotics act by feeding and stimulating the growth of various beneficial intestinal bacteria, whose metabolites also act to lower pH by increasing the amount of organic acids. On the other hand, they act by blocking
  • REPLACEMENT SHEETS (RULE 26) (mainly D-Mannose), immobilizing and reducing the ability of some pathogenic bacteria to attach to the intestinal mucosa and thus stimulating the immune system, reducing lesions in the walls of the intestinal mucosa and avoiding the indirect translocation of pathogens, which determine infections after reaching the bloodstream.
  • Oligosaccharides such as fructooligosaccharides (FOS) are polysaccharides which have demonstrated excellent prebiotic effects by selectively feeding some species of Lactobacillus and Bifidobacterium, thereby reducing the amount of other bacteria such as Bacteroides, Clostridium and coliforms.
  • Other prebiotics oligosaccharides are MOS (mananooligosaccharides), GOS (galactooligosaccharides), etc.
  • Arabinosis, galactose, mannose and mainly lactose are carbohydrates used as prebiotics.
  • Oligosaccharides can be obtained in the natural form in seeds and roots of some vegetables such as Yacon, chicory, onion, garlic, artichokes, leeks, asparagus, barley, rye, wheat, soybeans, chickpeas and lupine, for example. There are obtained oligosaccharides extracted by cooking, enzymatic or alcoholic action, and those obtained synthetically through the direct polymerization of some yeast cell wall disaccharides or fermentation of polysaccharides.
  • Bacteria present in the intestinal microbiota fulfill a number of functions useful and beneficial to hosts, whether humans or animals, among them the ability to metabolize nondigestible saccharides, regulate lipid metabolism, and biosynthesize vitamins.
  • this benefit goes much further, since the existence of a beneficial microbial population works by stimulating cell growth, suppressing the growth of harmful microorganisms, training the immune system to respond only to pathogens, and promoting defense against some diseases.
  • Pathogens can cause undesirable pathologies, as well as being prone to allergies, caused by excessive reactions of the immune system, due to the prevalence of C. difficile and S. aureus, and the lower prevalence of beneficial microorganisms such as Bacteroides and Bifidobacteria.
  • Salmonella is a genus of bacteria commonly called salmonella belonging to the family Enterobacteriaceae. They are gram-negative, rod-shaped bacteria, mostly mobile (with peritrichal flagella), non-sporulated, uncapped, have fimbriae, most of which do not ferment lactose.
  • the salmonella is a genus of bacteria commonly called salmonella belonging to the family Enterobacteriaceae. They are gram-negative, rod-shaped bacteria, mostly mobile (with peritrichal flagella), non-sporulated, uncapped, have fimbriae, most of which do not ferment lactose. The salmonella
  • REPLACEMENT SHEETS (RULE 26) are an extremely heterogeneous genus, composed of three species, Salmonella subterranea, Salmonella bongori and Salmonella enterica, the latter having about 2,610 serotypes.
  • the intestinal tract of man and animals is the main natural reservoir of this pathogen, with food of avian origin being important transmission routes.
  • Escherichia coli is a Gram-negative, anaerobic, facultative bacillary bacterium that does not produce spores. They have fimbriae or adhesins that allow their fixation, preventing the entrainment through the urine or diarrhea. They are part of the human microbiota and are mostly non-pathogenic. However some strains are considered pathogenic to produce enterotoxins. They have lipopolysaccharide (LPS), like most Gram-negative bacteria, which disproportionately activate the immune system and excessive vasodilatation caused by cytokines produced, which can lead to septic shock and death in cases of septicemia.
  • LPS lipopolysaccharide
  • MOS Motrololigosaccharides
  • immune modulators such as Betaglucans
  • prebiotics binding bacteria like MOS (Mannololigosaccharides), immune modulators such as Betaglucans and the prebiotics that promote the competitive exclusion, such as that caused by the bifidogenic effect of prebiotics such as FOS (Fruit-oligosaccharides) and GOS (Galactooligosaccharides), among others.
  • FOS Ferit-oligosaccharides
  • GOS Galactooligosaccharides
  • Prebiotics are defined as non-digestible food ingredients that benefit health as they stimulate the growth or activity of beneficial bacteria in our colon or intestinal tract.
  • Fructooligosaccharides (FOS) and galactooligosaccharides (GOS) are the most extensively studied prebiotics and have a proven bifidogenic effect.
  • Fructooligosaccharides or FOS are prebiotics that are also called oligofructose or oligofrutans, because they constitute the fructose oligosaccharides that can be used as sweeteners. They emerged in the 1980s as a response to consumers' tendency to employ low-calorie sweeteners. Fructooligosaccharides
  • REPLACEMENT SHEETS (RULE 26) (FOS) are obtained by processes of extraction and hydrolysis of the inulin molecule present in many plants and by the enzymatic reaction of transfructosylation of the sucrose molecule.
  • Inulin is a fructose polymer, or a polyfructose, with polymerization degree of 10 to 60.
  • Inulin can also be hydrolyzed into smaller molecules by chemical and enzymatic methods, generating mixtures of oligosaccharides with the general structure Glucose-Fructose or Gli- Fru n (abbreviation GF n ) and frum (Fm), with n ranging from 2 to 9 in varying from 2 to 10.
  • compositions of the commercial products may comprise questose (GF2), nystose (GF3), fructofuranosylnysthosis (GF3), inulobiosis (F2), inulotriose (F3) and inulotetraose (F4).
  • the second type of FOS is obtained by transfructosylation by the enzymes ⁇ -fructofuranosidade (invertase) and fructosyltransferase, present in many microorganisms, as for example Aspergillus niger, Aspergillus sp., Aureobasidium sp. This process generates a mixture of the general formula GFn with n ranging from 1 to 5. All these isomers and oligomers are called FOS.
  • MOS mannan-oligosaccharides
  • the bacteria Upon binding to mannose, the bacteria are physically and definitively captured by the MOS-containing particles and loaded out of the digestive tract along with the faecal cake.
  • the way of measuring the efficiency of each MOS source is by the amplitude and intensity of agglutination for the various species and serotypes of Salmonellas and E coli.
  • REPLACEMENT SHEETS enteritis, whose scarring calluses reduce the nutrient absorption capacity of the intestine.
  • MOS is particularly important in the case of animals since the health of the intestine allows a better absorption of the feed components.
  • antibiotics have been added to the composition of animal feeds at non-therapeutic levels, prophylactically, to prevent disease, improve the feed conversion ratio of feeds and accelerate growth, thus increasing the profitability of animal producers.
  • ⁇ -Glucans comprise a group of ⁇ -D-glucose polysaccharides that occur naturally in the walls of cereal, yeast, bacterial and fungal cells, exhibiting different physicochemical properties that depend on their source.
  • ⁇ -glucans typically have a linear structure with 1,3 ⁇ -glycosidic bonds, varying in their molecular weights, solubility, viscosity, branching, gelling properties, thus causing various effects on animal physiology.
  • Betaglucans and mannans are part of the cell wall structure of yeast and fungi.
  • yeasts of the genera Saccharomyces and Candida are those extracted from yeasts of the genera Saccharomyces and Candida.
  • the immunomodulatory effect of beta-glucans can be considered a physiological attack of the organism against these harmful bacteria. It manifests itself in the form of faster healing of the enteritis produced in the walls of the intestine, by these
  • REPLACEMENT SHEETS (RULE 26) bacteria, allowing a rapid coating of these walls by the protective mucus.
  • BR 0403979 relates to a nutritional or pharmaceutical composition for inhibiting the adhesion of pathogens to mammalian cells, or to preventing, reducing or inhibiting the invasion and infection of mammalian cells by pathogen, wherein the mammalian cells (GOS), curdlan (beta 1, glycosylcholines), glycosylcholines (GOS), glycogenoligosaccharides (GOS), glyceroligosaccharides, 3-glucan), sialyl-oligosaccharides, isomalto-oligosaccharides, oligogalacturonide, partially hydrolyzed agar, gentiololigosaccharides, arabino-oligosaccharides, pectin, lactose, lactulose, lactosucrose and long chain isomaltooligosaccharides.
  • GOS mammalian cells
  • curdlan beta 1, glycosylcholines
  • glycosylcholines glycosyl
  • BR 0813484 relates to a composition
  • a composition comprising: (A) an acidifying agent which may be selected from the group consisting of 2-hydroxy-4-methylthiobutanoic acid, formic acid, butyric acid, fumaric acid, lactic acid, benzoic acid , phosphoric acid, propionic acid, sorbic acid, and citric acid; (B) an immuno-stimulating agent which may be selected from the group consisting of a yeast derived product, a bacterial derived product and combinations thereof; and (C) an antioxidant which may be selected from the group consisting of 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, tertiary hydroquinone, butylated hydroxyanisole, butylated hydroxytoluene, gallic acid or acid derivative gallic, lecithin, ascorbic acid and tocopherol.
  • an acidifying agent which may be selected from the group consisting of 2-hydroxy-4-methylthiobutanoic acid, formic
  • BR 0611535 relates to a method for processing microorganism cells comprising: (A) autolysing the cells of the microorganism to release the cell walls of the microorganisms; (B) incubating the cell walls of the microorganism with an exogenous protease; (C) separating the cell walls of the microorganism into a glucan-enriched component and a mannan-enriched component; and (D) ultrafiltrating the mannan-enriched component of step (c) to form a filtrate and retentate, the mannan rich fraction being employed in animal feeds.
  • US 2012202770 relates to veterinary product or to animal feed.
  • REPLACEMENT SHEETS (RULE 26) animals for the treatment of diarrhea or intestinal disease associated with dietary Fabaceae protein in an animal, wherein said animal consumes the Fabaceae protein and wherein said treatment comprises the consumption of glucan or mannan.
  • US 2011250235 relates to a method of obtaining an immunomodulatory composition
  • an immunomodulatory composition comprising soluble yeast mannan, wherein the saccharide fraction comprises betal-6 glucan in 0.001 to 10% by dry weight percent and optionally said composition comprises mannan at 5 to 25% dry weight percent and the amount of ⁇ -glucan or ⁇ -glucans is less than 5%, dry weight percent.
  • compositions which refer to the use of various prebiotics in an alternative manner.
  • a particular composition may contain Betaglucans or MOS or FOS, and not cumulatively, for example, a composition containing Betaglucans and MOS and FOS as essential elements.
  • compositions which represent product with consequent characterizations of the type of process of obtaining the prebiotic, with type of raw material (sugar cane, or corn, or agave, or rice), type of fermentation and enzymes employed, different, and also process conditions such as temperature, fermentation time, additives employed, etc., also different from each other.
  • GOS Generic prebiotic terms, such as FOS, MOS, GOS, etc., hide complexities in their compositions, and are rarely pure. And even pure, several polymers carry the generic name of the group to which they belong, as is the case of lactulose and of the lactose itself, which are called by the man of the technique as being GOS.
  • FOS a product as if it were a simple compound and not a complex mixture of polymers, and still of different origins, and make comparisons of its performances against the microorganisms in general, not considering that the MOS by For example, it has better action on bacteria with type 1 fimbriae, beta-glucans serve to stimulate phagocytosis, and FOS and GOS have bifidogenic effects.
  • the effects of FOS, MOS, GOS and betaglucans can not be compared linearly, neither individually nor with each other.
  • REPLACEMENT SHEETS (RULE 26) (mannan-oligosaccharides from yeast cell walls used to obtain FOS).
  • a composition for use as an animal feed growth promoting additive having the following properties or advantages has been developed: A - It comprises in its formulation specific amounts of prebiotics: with different modes of action, so as to be capable of acting on several fronts in the broad spectrum of bacteria of the animal microbiota and, had comparable or superior efficiency to that of the growth promoting antibiotics;
  • B - Represented a product that modulates the intestinal microbiota: it contains a certain diversity of prebiotic types capable of having synergy between them, which have a strong growth promoting effect and a reduction in the population of undesirable bacteria, especially the various species and serotypes of Salmonella, Clostridium and E. co //, acting on 5 simultaneous fronts:
  • REPLACEMENT SHEETS * provoking the agglutination of bacteria with fimbriae type 1;
  • the present invention relates to a composition for additives suitable for use in animal feeds, such as growth promoters, or as nutraceuticals, or as prebiotics, or as additives for the control and prophylaxis of pathogenic bacteria in the intestinal tract of animals or farmed animals , which comprises 1,3 and 1,6 beta glucans and mannanoligosaccharides (MOS) and fructooligosaccharides (FOS) and / or inulin.
  • MOS mannanoligosaccharides
  • FOS fructooligosaccharides
  • composition of growth promoting prebiotic additives according to the invention may be employed in animal feeds, particularly for broiler growth and fattening, for heavy and laying matrices and in the initial and growth stages of pigs.
  • Prebiotics act by feeding and stimulating the growth of several beneficial intestinal bacteria (mainly Lactobacillus and Bifidobacteria), whose metabolites also act to reduce the pH of the intestinal endothelium by increasing the amount of organic acids.
  • beneficial intestinal bacteria mainly Lactobacillus and Bifidobacteria
  • lactic and butyric organic acids
  • REPLACEMENT SHEETS (RULE 26) the undesirable bacteria in the faecal cake.
  • they act by blocking adhesion sites (mainly D-Mannose), immobilizing and reducing the fixing capacity of some pathogenic bacteria in the intestinal mucosa, reducing lesions in the walls of the intestinal mucosa and avoiding the indirect translocation of pathogens, which infections after reaching the bloodstream.
  • adhesion sites mainly D-Mannose
  • microfragmented beta-glucans mimic constant bacterial attacks, which end up exerting phagocytosis and multiplying the macrophages, so that undesirable bacteria that eventually reach the intestinal endothelium are rapidly phagocytosed , preventing the formation of enteritis. Or, at least, allowing a quick healing of these.
  • Oligosaccharides such as fructooligosaccharides (FOS) are polysaccharides which have demonstrated excellent prebiotic effects by selectively feeding some species of Lactobacillus and Bifidobacterium, thereby reducing the amount of other bacteria such as Bacteroides, Clostridium and coliforms.
  • Other prebiotics oligosaccharides are MOS (mananooligosaccharides), GOS (galactooligosaccharides), etc.
  • the immunomodulatory and growth promoter composition and control of the undesirable bacterial populations of the intestinal microbiota in animals has a growth promoting effect analogous or superior to that of promoter antibiotics used for this purpose (APCs).
  • the prebiotics with bifidogenic effect which make up the invention, mostly represented by FOS and MOS, have the purpose of promoting a strong growth of the populations of Lactobacillus and Bifidobacteria, existing in the intestinal cecum.
  • the strong increase in the populations of these beneficial bacteria has the objective of performing the competitive exclusion of undesirable bacteria, acidifying the faecal cake in the region of its contact with the intestinal walls and increasing the production of protective mucus, as well as the quantity and the size of the villi intestinal diseases. All these benefits are aimed at improving feed conversion and assisting in the control of undesirable bacteria, especially Salmonella, Clostridium and E coli.
  • composition according to the invention comprises 1,3 and 1,6 beta glucans, mannanoligosaccharides (MOS), fructooligosaccharides (FOS) and / or inulin.
  • Mannanoligosaccharides are carbohydrates composed of 2 to 10 mannose residues, which can be obtained from galactomannans (GM).
  • GMs are polysaccharides composed of D-mannopyranose residues on ⁇ (1 - 4) bonds.
  • Mannanoligosaccharides are oligosaccharides whose source is yeast cell wall (dry yeast fermentation extract of the Saccharomyces or Candida genera). MOS contains fragments of the cell wall, as it is present on the surface of yeast cells and their walls where they represent 25 to 50% of their dry weight. The cells are broken down by autolysis, enzymatic hydrolysis or mechanical fragmentation, and the resulting mass is centrifuged to isolate the cell wall components, which are subsequently washed and dried by spray drying. The yeast wall has 80 to 85% polysaccharides, mainly glucans and mannans.
  • MOS are oligosaccharides that have mannose in their composition. Unlike FOS, it is not fermented by most intestinal bacteria. The presence of mannose provides a binding site for the pathogenic bacteria, which bind to the MOS and are carried by the peristaltic movements into the external environment, making colonization of the intestinal tract difficult.
  • MOS absorbs gram-negative bacteria containing type I fimbriae, preventing adhesion to intestinal villi and competition at the intestinal epithelial attachment sites, as well as modulating the host immune system.
  • Approximately 70% of E. coli and 53% of Salmonella sp. have type I fimbriae and one of the major concerns in the poultry industry is the threat of pathogenic bacteria associated with poultry products. Campylobacter, Clostridium, Escherichia coli and Samonella are the major pathogens associated with birds that cause disease in humans.
  • MOS manno-oligosaccharides
  • REPLACEMENT SHEETS (RULE 26) Salmonella and E. coli, because they adhere the intestinal walls, causing enteritis that prevent an improvement of the feed conversion.
  • a secondary mechanism of action of MOS is the inhibition of the presence of certain fungi, which are equally undesirable for improved feed conversion.
  • the MOS or mannanoligosaccharides of the composition of this invention are responsible for the agglutination of bacteria having type 1 fimbriae and must come from yeast cell walls of the genera Saccharomyces or Candida. Preferably, from Saccharomyces cerevisiae from the production of ethanol from sugarcane.
  • MOS is preferably to be extracted from the hydrolysis promoted by the action of commercial proteases added on yeasts of Saccharomyces cerevisae.
  • other types of MOS originating from other species of yeast and obtained by other extraction processes may also be used in the composition of this invention. Including, the MOS contained in whole dry yeasts and non-hydrolysed cell walls of yeasts in general, produced in different musts, whether in primary or secondary fermentations.
  • the prebiotic additive composition comprises 11% to 3% by weight of MOS or mananooligosaccharides. Preferably, the composition should contain 7% MOS.
  • Beta-glucans are polysaccharides of D-glucose monomers linked by ⁇ -type glycosidic linkages. Beta-glucans vary in molecular mass, solubility, viscosity and three-dimensional configuration. In nature they occur as cellulose in plants, or in bran cereal grains, yeast cell walls, in certain fungi, mushrooms and bacteria.
  • beta-glucans are those comprising D-glucose units attached to one another in position (1,3) with D-glucose side chains attached at the (1,6) position, which are called of beta-glucans 1,3 / 1,6 glucan.
  • the frequency, location, and length of the side chain rather than the backbone that determines its activity along the immune system is believed.
  • Insoluble beta-glucans (1.3 / 1.6) have higher biological activity than soluble beta-glucans (1.3 / 1.4).
  • beta-glucans are from yeast walls such as Saccharomyces cerevisae.
  • REPLACEMENT SHEETS (RULE 26) [061]
  • the mechanism of action of the 1,3 and 1,6 Betaglucans is the modulation of the immune system in general and especially the one connected to the digestive system, stimulating the multiplication of the macrophages and their phagocytosis activity of the unwanted bacteria that adhere to the intestinal walls or that eventually invade the lymphatic system. Both are undesirable to an improved feed conversion.
  • the prebiotic additive composition comprises 20% to 7% by weight of beta glucans, particularly 1,3 and 1,6 beta glucans.
  • the composition should contain 14% of 1,3 and 1,6 Betaglucans.
  • Betaglucans of the composition of this invention are responsible for stimulation of the immune system and must be derived from yeast cell wall extraction from the Saccharomyces or Candida genera, preferably from Saccharomyces cerevisiae, from the sugar cane ethanol production.
  • the preferred process of extraction and fractionation of Betaglucans is based on the use of commercial proteases and betaglucanases added on the yeasts of Saccharomyces cerevisae, derived from the production of ethanol from sugar cane.
  • Betaglucans from primary or secondary fermentations of other types of must, from other species and extracted by other processes, including non-enzymatic processes, may also be used in the composition of this invention.
  • Natural fructooligosaccharides are extracted from Blue Agave as well as from fruits and vegetables such as bananas, onions, chicory, garlic, asparagus, etc.
  • FOS are sugar polymers rich in fructose. With a similar structure, but of different size, there is inulin, a polymer found in vegetables.
  • the FOS are fermented mainly by Bifidobacterium and Lactobacillus, in such a way that they stimulate the growth of populations beneficial to the intestine.
  • These bacteria mainly produce lactic and butyric acid, which is reflected in the reduction of the pathogenic population by the acidification of the environment near the intestinal endothelium.
  • fructooligosaccharides are obtained by degradation of inulin or polyfructose, a polymer of ⁇ -fructose residues linked by ⁇ (1 - 2) linkages with a ⁇ -linked linkage of D (1 - 2).
  • the degree of polymerization of inulin ranges from 10 to 60.
  • Inulin can be enzymatically or chemically degraded in a mixture of oligosaccharides having a general structure Glu-Frun (abbreviation GFn) and Frum
  • REPLACEMENT SHEETS (RULE 26) (Fm), with neither ranging from 1 to 7. As this process also occurs in nature we can find these oligosaccharides in plants as well.
  • the main components of the commercial products are kestose (GF2), nystose (GF3), fructosylnysteosis (GF4), bifurcose (GF3), inulobiosis (F2), inulotriose (F3) and inulotetraose (F4).
  • FOS synthesis addresses the transfructosylation by the action of ⁇ -fructosidase from Asperguillus niger or Aureobasidium sp. on sucrose molecules.
  • the resulting product has the general formula GFn, where n can vary from 1 to 5.
  • n can vary from 1 to 5.
  • the fructooligosaccharides resist the hydrolysis by the action of the saliva and digestive enzymes of the intestine. In the colon they are fermented by anaerobic bacteria, for this reason they represent food with low calorific content, however they contribute to the fiber fraction of the diet.
  • Fructooligosaccharides are more soluble than inulins.
  • This invention employs FOS comprising in particular kestose (GF2), nystose (GF3), fructosylnysteosis (GF4).
  • FOS comprising in particular kestose (GF2), nystose (GF3), fructosylnysteosis (GF4).
  • FOS molecules that are not digestible in the small intestine are fermented in the large intestine by the anaerobic bacteria that make up the intestinal microbiota, producing large amounts of short-chain fatty acids or volatile fatty acids, among them: acetic acid, propionic acid and butyric acid, in addition to CO2, ammonia and H2 and, as a result, the pH, together with the intestinal endothelium of the large intestine, chasing undesirable bacteria and increasing the absorption of minerals, mainly calcium.
  • Bifidobacteria and Lactobacillus are resistant to the acid medium, while harmful bacteria like Clostridium, E. coli, Salmonella, among others, are sensitive to this medium.
  • the FOS or Fructooligosaccharides of the composition of this invention should preferably be of the type containing only short chain polymers which have a higher bifidogenic effect, i.e. comprise GF2, GF3 and GF4.
  • these are derived from the fermentation and biotransformation of sugarcane sucrose by enzymes produced by yeasts of the genus Aureobasidium.
  • FOS Fructooligosaccharides of the composition of this invention
  • REPLACEMENT SHEETS (RULE 26) may also be used as the FOS component of the composition of this invention.
  • the prebiotic additive composition comprises 12% to 45% by weight of FOS or fructooligosaccharides. Preferably, the composition should contain 35% FOS.
  • Inulin according to the invention may be represented by any fructan.
  • composition may further contain acidifying agents (short chain organic acids), minerals (in inorganic form or linked to organic molecules), probiotics, tannins, essential oils, etc.
  • acidifying agents short chain organic acids
  • minerals in inorganic form or linked to organic molecules
  • probiotics probiotics
  • tannins essential oils
  • the composition according to the invention may contain mineral micronutrients, in inorganic forms or associated with organic molecules, preferably Zinc, Manganese, Magnesium and Copper chelated and organic selenium, whose action is immunomodulatory.
  • the present invention is especially intended for creations where control of undesirable bacteria is more important, as is the case of Salmonellas in the fattening stage of chickens and Clostridium, E coli and Salmonella in swine (diarrhea-causing agents), and Salmonella galinarum in laying hens.
  • the composition according to the invention is intended primarily for the control of undesirable bacteria, although it is also a good growth promoter.
  • the most indicated creations are growth and fattening of
  • REPLACEMENT SHEETS (RULE 26) chickens, laying hens, heavy chicks and early stages and growth of pigs.
  • Treatment 1 Basal diet with halquinol addition as growth promoter
  • Treatment 2 Basal diet with addition of GLUCAN MOS, (2kg / t of feed);
  • Treatment 3 Basal diet with addition of GLUCAN MOS, (3kg / t of feed);
  • Treatment 4 Basal diet with addition of GLUCAN MOS (67%) + FOS (33%), (2kg / t of ration);
  • Treatment 5 Basal diet with addition of GLUCAN MOS (67%) + FOS (33%), (3 kg / t of feed).
  • Table 4 below indicates the average daily feed intake (CDR), daily gain of weight (GW) and feed conversion rate (CA) of piglets during the first 15 days of experiment (Pre-Initial Phase I):
  • Table 5 below indicates the average daily feed intake (CDR), daily gain of weight (GW) and feed conversion (CA) of piglets during the first 28 days of experimentation (Pre-Initial and Pre-Initial Phases II):
  • Table 6 below indicates the average daily feed intake (CDR), daily gain of weight (GW) and feed conversion (CA) of piglets during the total experimental period (41 days);
  • Table 7 indicates the average daily feed intake (CDR), daily gain of weight (GW) and feed conversion (CA) of piglets during the total experimental period (41 days);
  • Table 8 below indicates the economic results of the treatments, showing daily costs of the additives (ADC), the daily benefits (BD - CDR and GDP) and the benefit / cost ratio provided by treatments, piglets during the period
  • composition according to this invention was able to substitute the antibiotic as growth promoter (APC), presenting better feed conversion rates in all phases tested.
  • APC growth promoter
  • compositions were made according to the invention to be tested as growth promoting and auxiliary additives in the control of Salmonella in chickens inoculated with Salmonella enteritidis.
  • the compositions used the raw materials listed below in Table 9 below:
  • compositions of Examples 2, 3 and 4 presented mass contents of the components on the final composition according to the invention as shown in Table 10 below:
  • compositions of examples 2, 3 and 4 were used as growth promoting additives for growing chicken feeds, that is, for the first 28 days of life, to evaluate the productive performance and control of Salmonella enteritidis.
  • a total of 300 broilers of the commercial Ross lineage were divided into 5 treatments with six replicates of 10 animals each.
  • On the fourth day all birds were inoculated with Salmonella enteritidis.
  • Weight control, feed intake and suabe propé test were performed weekly to evaluate the presence of Salmonella in aviaries' bed.
  • T2 Basal diet + GlucanMOS - 2 kg / t of ration
  • T3 Basal Diet + Composition of Example 3 - 2 kg / t of feed
  • T4 Basal Diet + Composition of Example 4 - 3 kg / t of ration
  • PF is the mean final weight of the animals of each treatment
  • CM is the average feed intake of the animals from each treatment and the feed conversion ratio of each treatment.
  • REPLACEMENT SHEETS (RULE 26) treated as a therapeutic antibiotic.
  • those of Example 2 and 3 were the ones that presented better feed conversion.
  • the best Benefit / Cost (BC) ratios were obtained with GlucanMOS and the composition of Example 4. That is, when it comes to feed conversion, the best technical solution is not always the best economic development.
  • CMA is the average cost of the additive, per animal, during the experiment period (28 days).
  • BM is the average benefit provided by each additive (variation of feed intake and daily weight gain) during the 28 days of the experiment.
  • B / C is the benefit / cost ratio provided by each additive when analyzing only the CA.
  • Example 26 REPLACEMENT SHEETS (RULE 26) than the therapeutic antibiotic, since it eliminated Salmonella from the aviary bed in less than two weeks.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

La présente invention concerne une composition pour additifs prébiotiques promoteurs de croissance utilisables dans des rations animales, ou comme promoteurs de croissance, ou comme nutraceutiques, ou comme prébiotiques, ou comme additifs pour le contrôle et la prophylaxie de bactéries pathogènes dans le tractus intestinal des animaux, ou d'animaux d'élevage. Il a été procédé à la mise au point d'une composition d'additifs prébiotiques pour rations d'animaux comprenant des 1,3 et 1,6 bêtaglucanes et des manano-oligosaccharides (MOS) et des fruto-oligosaccharides (FOS) et/ou de l'inuline. La composition d'additifs prébiotiques promoteurs de croissance peut être utilisée dans des rations animales, notamment pour la croissance et l'engraissement de poulets, pour les pondeuses, pour les reproducteurs de poussins à griller et dans la phase initiale et de croissance de porcins.
PCT/BR2018/050316 2017-09-06 2018-09-04 Composition d'additifs prébiotiques promoteurs de croissance pour rations animales et son utilisation Ceased WO2019046919A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR1020170191869 2017-09-06
BR102017019186-9A BR102017019186A2 (pt) 2017-09-06 2017-09-06 Composição de aditivos prebióticos promotores de crescimento para rações animais e seu uso

Publications (1)

Publication Number Publication Date
WO2019046919A1 true WO2019046919A1 (fr) 2019-03-14

Family

ID=62043580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2018/050316 Ceased WO2019046919A1 (fr) 2017-09-06 2018-09-04 Composition d'additifs prébiotiques promoteurs de croissance pour rations animales et son utilisation

Country Status (3)

Country Link
AR (1) AR112997A1 (fr)
BR (1) BR102017019186A2 (fr)
WO (1) WO2019046919A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4094769A1 (fr) * 2021-05-27 2022-11-30 Beghin, Meiji Composition et procédé pour équilibrer le microbiote intestinal, le système immunitaire et la fonction métabolique des sujets âgés
WO2024130376A1 (fr) * 2022-12-23 2024-06-27 Yessinergy Holding S.A. Composition pour promouvoir la multiplication et la survie de micro-organismes, procédé de traitement de plantes et utilisation de la composition dans des biopesticides agricoles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061345A1 (en) * 1996-12-23 2002-05-23 Juhani Vuorenmaa Procedure for preparing a food additive, and an additive and its use
BRPI0611535A2 (pt) * 2005-05-05 2010-09-21 Sensient Flavors Inc métodos para processar células de microorganismos e células de levedura, composição, suplemento alimentar, produto farmacêutico, cosmético ou produto nutracêutico e ração animal
US20120121621A1 (en) * 2005-06-13 2012-05-17 Jaszberenyi Csaba Jozsef Synergistic prebiotic compositions
WO2016122887A1 (fr) * 2015-01-26 2016-08-04 Midori Usa, Inc. Compositions à base d'oligosaccharides destinées à être utilisées comme aliment pour animaux et procédés de production de celles-ci
WO2017083520A1 (fr) * 2015-11-13 2017-05-18 Cadena Bio, Inc. Compositions alimentaires et thérapeutiques pour animaux et méthodes d'utilisation
BR102016014961A2 (pt) * 2016-06-24 2018-01-02 Yessinergy Holding S/A composição imuno-moduladora e promotora de controle da população de bactérias indesejáveis da microbiota intestinal

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061345A1 (en) * 1996-12-23 2002-05-23 Juhani Vuorenmaa Procedure for preparing a food additive, and an additive and its use
BRPI0611535A2 (pt) * 2005-05-05 2010-09-21 Sensient Flavors Inc métodos para processar células de microorganismos e células de levedura, composição, suplemento alimentar, produto farmacêutico, cosmético ou produto nutracêutico e ração animal
US20120121621A1 (en) * 2005-06-13 2012-05-17 Jaszberenyi Csaba Jozsef Synergistic prebiotic compositions
WO2016122887A1 (fr) * 2015-01-26 2016-08-04 Midori Usa, Inc. Compositions à base d'oligosaccharides destinées à être utilisées comme aliment pour animaux et procédés de production de celles-ci
WO2017083520A1 (fr) * 2015-11-13 2017-05-18 Cadena Bio, Inc. Compositions alimentaires et thérapeutiques pour animaux et méthodes d'utilisation
BR102016014961A2 (pt) * 2016-06-24 2018-01-02 Yessinergy Holding S/A composição imuno-moduladora e promotora de controle da população de bactérias indesejáveis da microbiota intestinal

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUNA ET AL.: "Mananoligossacarideo e beta-glucano em dietas de leitões desmamados", ARQUIVO BRASILEIRO DE MEDICINA VETERINÁRIA E ZOOTECNIA, vol. 67, no. 2, 2015, pages 591 - 599, XP055581639, DOI: 10.1590/1678-7146 *
SILVA ET AL.: "Inulina na produção de frangos de corte", SCIENTIA AGRARIA PARANAENSIS, vol. 11, no. 3, 2012, pages 16 - 24, XP055581643 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4094769A1 (fr) * 2021-05-27 2022-11-30 Beghin, Meiji Composition et procédé pour équilibrer le microbiote intestinal, le système immunitaire et la fonction métabolique des sujets âgés
WO2022248637A1 (fr) * 2021-05-27 2022-12-01 Beghin Meiji Composition et procédé d'équilibrage du système immunitaire et de la fonction métabolique chez des sujets humains et/ou animaux
WO2024130376A1 (fr) * 2022-12-23 2024-06-27 Yessinergy Holding S.A. Composition pour promouvoir la multiplication et la survie de micro-organismes, procédé de traitement de plantes et utilisation de la composition dans des biopesticides agricoles

Also Published As

Publication number Publication date
BR102017019186A2 (pt) 2018-02-27
AR112997A1 (es) 2020-01-15

Similar Documents

Publication Publication Date Title
Jha et al. Dietary fiber in poultry nutrition and their effects on nutrient utilization, performance, gut health, and on the environment: a review
Knudsen et al. The role of carbohydrates in intestinal health of pigs
Vidanarachchi et al. Phytobiotics: alternatives to antibiotic growth promoters in monogastric animal feeds
Sundu et al. Palm kernel meal in broiler diets: effect on chicken performance and health
Flickinger et al. Nutritional responses to the presence of inulin and oligofructose in the diets of domesticated animals: a review
Adebowale et al. Major cereal carbohydrates in relation to intestinal health of monogastric animals: A review
Molist et al. Relevance of functional properties of dietary fibre in diets for weanling pigs
Regassa et al. Application of resistant starch in swine and poultry diets with particular reference to gut health and function
Flickinger et al. Pet food and feed applications of inulin, oligofructose and other oligosaccharides
Hajati et al. The application of prebiotics in poultry production
Sweeney et al. Effect of purified β-glucans derived from Laminaria digitata, Laminaria hyperborea and Saccharomyces cerevisiae on piglet performance, selected bacterial populations, volatile fatty acids and pro-inflammatory cytokines in the gastrointestinal tract of pigs
Bindelle et al. Nutritional and environmental consequences of dietary fibre in pig nutrition: a review
Bogusławska-Tryk et al. Dietary fructans and their potential beneficial influence on health and performance parametrs in broiler chickens
EP3476226B1 (fr) Composition immunomodulatrice et promotrice de la croissance et du contrôle de la population de bactéries indésirables du microbiote intestinal
CN104758318B (zh) 一种降低断奶仔猪腹泻率的复合制剂及其制备方法
Flis et al. Fiber substrates in the nutrition of weaned piglets–a review
Zduńczyk et al. Determinants and effects of postileal fermentation in broilers and turkeys part 1: gut microbiota composition and its modulation by feed additives
US9028861B2 (en) Method and composition to reduce diarrhea in a companion animal
Sundu et al. Potential use of beta-mannan from copra meal as a feed additive for broilers
Juśkiewicz et al. Performance and gastrointestinal tract metabolism of turkeys fed diets with different contents of fructooligosaccharides
Pieper et al. Dietary fibre and crude protein: impact on gastrointestinal microbial fermentation characteristics and host response
Morgan Advances in prebiotics for poultry: role of the caeca and oligosaccharides
WO1995017103A1 (fr) Utilisation de materiaux riches en mannane dans des aliments de l'homme et des animaux
Chen et al. Effects of Armillariella tabescens mycelia on the growth performance and intestinal immune response and microflora of early‐weaned pigs
WO2019046919A1 (fr) Composition d'additifs prébiotiques promoteurs de croissance pour rations animales et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18854973

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18854973

Country of ref document: EP

Kind code of ref document: A1